echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Yangzijiang Pharmaceuticals' "Entikave Oral Solution" was approved for the first time

    Yangzijiang Pharmaceuticals' "Entikave Oral Solution" was approved for the first time

    • Last Update: 2021-01-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Enticave (ETV) is a nucleoside antiviral drug used in the treatment of chronic hepatitis B.
    the drug was first developed by Shishi Shiguibao, first approved in China in 2005, has become a first-line treatment of hepatitis B drugs.
    public data show that in 2019, the domestic public medical institutions terminal Endikave sales of more than 7 billion yuan, but mainly tablets and capsules, the market share with a positive day, 48.93 percent, the original research ShiGuibao accounted for 26.44 percent.
    The Insight database shows that there are currently six dosage forms in the country, including tablets, dispersion tablets, capsules, oral solutions, particles and Malay acid entecawe tablets.
    , the first three of them have been included in the 4 plus 7 episodes, the 33 in this Yangzijiang before the approval, there has not been a domestic generic drug approval.
    from: Insight database () for Entekave oral solution, the original research hundred-time Meishi Guibao pharmaceutical is still in clinical applications, there are few domestic enterprises to apply.
    addition to the yangzijiang pharmaceutical industry approved this time, Only Anhui New Century Pharmaceuticals submitted a new registration classification listing application on September 17 this year.
    addition, Stadt Pharmaceuticals was approved for clinical practice in December 2019.
    from: Insight Database ()
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.